Minimally invasive epicardial left-ventricular lead implantation and simultaneous left atrial appendage closure.
atrial fibrillation
epicardial lead placement
left atrial appendage closure
minimally-invasive
totally thoracoscopic
Journal
Frontiers in cardiovascular medicine
ISSN: 2297-055X
Titre abrégé: Front Cardiovasc Med
Pays: Switzerland
ID NLM: 101653388
Informations de publication
Date de publication:
2023
2023
Historique:
received:
21
12
2022
accepted:
15
02
2023
entrez:
27
3
2023
pubmed:
28
3
2023
medline:
28
3
2023
Statut:
epublish
Résumé
Atrial fibrillation (AF) is common in patients with heart failure resulting in a high prevalence of AF in patients receiving Cardiac Resynchronization Therapy (CRT) implantation. In patients, unsuitable for transvenous left ventricular (LV)-lead implantation, epicardial LV-lead implantation represents a valuable alternative. Epicardial LV-lead placement can be achieved totally thoracoscopical or Between December 2019 and March 2022, 8 patients received minimally invasive left atrial LV-lead implantation with concomitant LAA closure using the AtriClip. Transesophageal echocardiography (TEE) was performed to intraoperatively guide and control LAA closure. Mean patients age was 64 ± 11.2 years, 67% were male patients. Minimally invasive left-lateral thoracotomy was used in 6 patients while a totally thoracoscopic approach was performed in 2 cases. Epicardial lead implantation was successfully performed in all patients with good pacing threshold (mean 0.8 ± 0.2 V) and sensing values (10.1 ± 2.3 mV). Posterolateral position of the LV lead was achieved in all patients. Furthermore, successful LAA closure was confirmed during TEE in all patients. No procedure-related complications occurred in any of the patients. Two patients additionally received simultaneous laser lead extraction during the same procedure. Complete lead extraction was achieved in both patients. All patients were extubated in the OR and had an uneventful postoperative course. Our study highlights a novel treatment approach for patients with atrial fibrillation and the necessity of epicardial LV leads. Placement of a posterolateral LV lead position with concomitant occlusion of the left atrial appendage
Sections du résumé
Background
UNASSIGNED
Atrial fibrillation (AF) is common in patients with heart failure resulting in a high prevalence of AF in patients receiving Cardiac Resynchronization Therapy (CRT) implantation. In patients, unsuitable for transvenous left ventricular (LV)-lead implantation, epicardial LV-lead implantation represents a valuable alternative. Epicardial LV-lead placement can be achieved totally thoracoscopical or
Methods
UNASSIGNED
Between December 2019 and March 2022, 8 patients received minimally invasive left atrial LV-lead implantation with concomitant LAA closure using the AtriClip. Transesophageal echocardiography (TEE) was performed to intraoperatively guide and control LAA closure.
Results
UNASSIGNED
Mean patients age was 64 ± 11.2 years, 67% were male patients. Minimally invasive left-lateral thoracotomy was used in 6 patients while a totally thoracoscopic approach was performed in 2 cases. Epicardial lead implantation was successfully performed in all patients with good pacing threshold (mean 0.8 ± 0.2 V) and sensing values (10.1 ± 2.3 mV). Posterolateral position of the LV lead was achieved in all patients. Furthermore, successful LAA closure was confirmed during TEE in all patients. No procedure-related complications occurred in any of the patients. Two patients additionally received simultaneous laser lead extraction during the same procedure. Complete lead extraction was achieved in both patients. All patients were extubated in the OR and had an uneventful postoperative course.
Conclusion
UNASSIGNED
Our study highlights a novel treatment approach for patients with atrial fibrillation and the necessity of epicardial LV leads. Placement of a posterolateral LV lead position with concomitant occlusion of the left atrial appendage
Identifiants
pubmed: 36970346
doi: 10.3389/fcvm.2023.1129410
pmc: PMC10036564
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1129410Informations de copyright
© 2023 Petersen, Alassar, Yildirim, Tönnis, Reichenspurner and Pecha.
Déclaration de conflit d'intérêts
SP is a consultant for Philips Healthcare. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Circulation. 2016 Feb 2;133(5):484-92
pubmed: 26746177
Heart Rhythm. 2019 Sep;16(9):e128-e226
pubmed: 30412778
Circulation. 2009 May 12;119(18):2516-25
pubmed: 19433768
Europace. 2022 Oct 13;24(10):1627-1635
pubmed: 35718878
Europace. 2013 Aug;15(8):1205-9
pubmed: 23426553
Circulation. 2010 Jul 13;122(2):109-18
pubmed: 20606120
Lancet. 2009 Aug 15;374(9689):534-42
pubmed: 19683639
JAMA Surg. 2019 Aug 1;154(8):755-766
pubmed: 31054241
Am J Cardiol. 2003 Mar 20;91(6A):2D-8D
pubmed: 12670636
Clin Cardiol. 2020 Mar;43(3):284-290
pubmed: 31837030
J Am Coll Cardiol. 2014 Jul 8;64(1):1-12
pubmed: 24998121
J Cardiovasc Dev Dis. 2022 May 16;9(5):
pubmed: 35621871
Europace. 2020 Apr 1;22(4):515-549
pubmed: 31702000
N Engl J Med. 2021 Jun 3;384(22):2081-2091
pubmed: 33999547
J Card Surg. 2021 Nov;36(11):4403-4406
pubmed: 34418154
Interact Cardiovasc Thorac Surg. 2022 Mar 31;34(4):548-555
pubmed: 34871377
J Clin Med. 2022 Nov 01;11(21):
pubmed: 36362719
Eur J Cardiothorac Surg. 2017 Jun 1;51(6):1108-1111
pubmed: 28204134
Interact Cardiovasc Thorac Surg. 2020 Jan 1;30(1):74-80
pubmed: 31633187